SCHEMBL6036258

SCHEMBL6036258

Cc1cccc(CC(=O)O)c1OCCCc1cn(-c2ccc(C(F)(F)F)cn2)nc1C(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.37
LMNA P02545 2/20 0.37
HTT P42858 2/20 0.37
KDM4E B2RXH2 1/20 0.37
PPARD Q03181 5/20 0.37
PPARA Q07869 3/20 0.37
PPARG P37231 2/20 0.37
HPGD P15428 1/20 0.36
MAPT P10636 3/20 0.35
ALDH1A1 P00352 2/20 0.35
POLB P06746 1/20 0.35
THRB P10828 1/20 0.35
AGBL2 Q5U5Z8 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
PTGER1 P34995 1/20 0.34
PTGER4 P35408 1/20 0.34
PTGER3 P43115 1/20 0.34
PTGER2 P43116 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6035821 0.92 SMN1; SMN2 (0.36) SMN1; SMN2LMNAHTTKDM4EPPARD
SCHEMBL6035550 0.90 PPARG (0.40) SMN1; SMN2LMNAHTTKDM4EPPARD
SCHEMBL6034691 0.88 SMN1; SMN2 (0.36) SMN1; SMN2LMNAHTTKDM4EPPARD
SCHEMBL6035417 0.88 SMN1; SMN2 (0.36) SMN1; SMN2LMNAHTTKDM4EPPARD
SCHEMBL6035756 0.88 PTGER4 (0.35) PPARDPPARAPPARGMAPTALDH1A1
SCHEMBL6035698 0.88 ABCB1 (0.38) KDM4EPPARDPPARAPPARGALDH1A1
SCHEMBL6035913 0.87 SMN1; SMN2 (0.35) SMN1; SMN2LMNAHTTKDM4EPPARD
SCHEMBL1635158 0.86 PTGER4 (0.34) PPARDPPARAPPARGALDH1A1PTGER1
SCHEMBL6035958 0.86 SMN1; SMN2 (0.35) SMN1; SMN2LMNAHTTKDM4EPPARD
SCHEMBL6035076 0.85 GCGR (0.39) SMN1; SMN2LMNAHTTKDM4EPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 SMN1; SMN2 4408/4885LMNA 1816/4885HTT 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.